International
The Morning Science

What science found today

‹
 

Research

'Grand Slam' Pancreatic Cancer Drug Shows Promise as First-Line Treatment

MedPage Today ·

'Grand Slam' Pancreatic Cancer Drug Shows Promise as First-Line Treatment

The Brief

  • The first-in-class RAS inhibitor daraxonrasib (Rasonque), combined with chemotherapy, showed promise as a first-line treatment for metastatic pancreatic adenocarcinoma (PDAC).
  • The reported results come from an early-stage study.
  • Source coverage is a short excerpt, so trial size, endpoints and safety data are not available here.

Why it matters

If later trials confirm these early results, a RAS inhibitor combined with chemotherapy could become a new first-line option for metastatic pancreatic cancer, a disease with limited treatment choices.

Who’s affected

  • oncologists and pancreatic cancer researchers
  • patients with metastatic pancreatic adenocarcinoma

(MedPage Today) -- The first-in-class RAS inhibitor daraxonrasib (Rasonque) in combination with chemotherapy showed promise as a first-line treatment for patients with metastatic pancreatic adenocarcinoma (PDAC), according to results from an early...

How do you feel about this?

0 Comments

    'Grand Slam' Pancreatic Cancer Drug Shows Promise as First-Line Treatment – The Morning Science